Clarus Ventures

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Malvern, Pennsylvania, dedicated to developing innovative therapeutics aimed at enhancing the effectiveness of radiotherapy for cancer patients. The company's lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer. Additionally, GC4419 is being evaluated in Phase IIa trials for the treatment of radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing another candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. The company's research is focused on targeting oxygen metabolic pathways to improve patient outcomes in radiation therapy, and GC4419 has received Fast Track and Breakthrough Therapy designations from the U.S. Food and Drug Administration.

Avrobio is a clinical-stage gene therapy company based in Cambridge, Massachusetts, focused on developing ex vivo lentiviral gene therapies aimed at treating rare diseases with a single-dose approach. The company utilizes hematopoietic stem cells collected from patients, which are modified using a lentiviral vector to insert functional copies of defective genes associated with specific diseases. Avrobio's lead product candidate, AVR-RD-01, is currently in Phase II clinical trials for Fabry disease. Additionally, the company's pipeline includes AVR-RD-02, which has completed preclinical trials for type 1 Gaucher disease; AVR-RD-03, in preclinical development for Pompe disease; and AVR-RD-04, which has also completed preclinical studies for cystinosis. Avrobio has established a research collaboration with Magenta Therapeutics to explore targeted antibody-drug conjugates as a conditioning regimen for its lentiviral gene therapies. Founded in 2015, Avrobio aims to leverage advancements in cell and gene therapies to provide potential cures for serious and debilitating conditions.

Forty Seven, Inc. is a clinical-stage immuno-oncology company based in Menlo Park, California, focused on developing innovative therapies to activate macrophages in the fight against cancer. The company's lead candidate, a monoclonal antibody targeting the CD47 receptor, aims to counteract the "don't eat me" signal that cancer cells use to evade the immune system. This antibody is currently undergoing evaluation in multiple clinical trials for various cancers, including solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma, and colorectal carcinoma. In addition to its flagship program, Forty Seven is advancing other antibodies, such as FSI-189, which binds to SIRPa, and FSI-174, an anti-cKIT antibody. The company has established collaborations with Genentech and Acerta Pharma to explore additional treatment combinations in non-Hodgkin's lymphoma and diffuse large B-cell lymphoma. Founded in 2014, Forty Seven operates as a subsidiary of Gilead Sciences.

Gritstone bio is a biotechnology company focused on developing personalized immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surfaces of infected cells. This approach leverages the immune system's ability to recognize abnormal cell targets, which is crucial for both anti-tumor and anti-viral immunity. Gritstone bio is building a robust pipeline of immunotherapy product candidates, including GRANITE, SLATE, and CORAL, designed to address various solid tumors. Through these developments, Gritstone bio aims to contribute to the evolving landscape of cancer treatment and enhance patient outcomes.

PATH is an international nonprofit organization that transforms global health through innovation. They take an entrepreneurial approach to developing and delivering high-impact, low-cost solutions, from lifesaving vaccines and devices to collaborative programs with communities. Through our work in more than 70 countries, PATH and our partners empower people to achieve their full potential.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company specializes in developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By focusing on these mechanisms, Cleave Therapeutics aims to create enzyme inhibitors that can effectively treat cancer and neurodegenerative diseases. Its research efforts are directed toward discovering innovative therapies that may improve patient outcomes in oncology.

Avrobio is a clinical-stage gene therapy company based in Cambridge, Massachusetts, focused on developing ex vivo lentiviral gene therapies aimed at treating rare diseases with a single-dose approach. The company utilizes hematopoietic stem cells collected from patients, which are modified using a lentiviral vector to insert functional copies of defective genes associated with specific diseases. Avrobio's lead product candidate, AVR-RD-01, is currently in Phase II clinical trials for Fabry disease. Additionally, the company's pipeline includes AVR-RD-02, which has completed preclinical trials for type 1 Gaucher disease; AVR-RD-03, in preclinical development for Pompe disease; and AVR-RD-04, which has also completed preclinical studies for cystinosis. Avrobio has established a research collaboration with Magenta Therapeutics to explore targeted antibody-drug conjugates as a conditioning regimen for its lentiviral gene therapies. Founded in 2015, Avrobio aims to leverage advancements in cell and gene therapies to provide potential cures for serious and debilitating conditions.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from classical complement-mediated disorders affecting the body, brain, and eye. The company's research is centered around its platform technology that targets classical complement-mediated autoimmune and neurodegenerative diseases associated with the abnormal activation of C1q, a key molecule in the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody intended for intravenous use in treating autoimmune and neurodegenerative disorders. Another candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration aimed at neurodegenerative ophthalmic conditions. The company employs a disciplined, biomarker-driven development strategy to ensure its therapies effectively engage the target at tolerable doses within the intended patient tissues, while also exploring additional indications within both orphan and larger market segments.

Flowonix Medical, Inc. is a medical device company focused on developing innovative solutions for chronic disorders through targeted drug delivery systems. The company has created an implantable drug pump designed to deliver therapeutic drugs directly into the spine, addressing the needs of patients suffering from various neurological conditions and long-term pain. Its main product, the Prometra system, includes the Prometra Pump, which ensures precise dosing, and a specialized catheter for effective drug placement within the intrathecal space. Founded in 2005 and headquartered in Mount Olive, New Jersey, with an additional office in Mansfield, Massachusetts, Flowonix aims to improve patient quality of life by providing physicians with reliable tools for managing chronic pain and neurological disorders.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company focuses on chronic vision-threatening conditions. Its lead product candidate, GB-102, is an intravitreal injection undergoing clinical trials for wet age-related macular degeneration and diabetic macular edema. Additionally, Graybug is advancing GB-103, a once-a-year formulation aimed at treating diabetic retinopathy, and GB-401, a depot formulation targeting primary open-angle glaucoma. The company utilizes proprietary micro- and nanoparticle controlled release technologies to enhance drug delivery in ocular tissues, thereby improving patient compliance and clinical outcomes. Graybug Vision was previously known as Graybug LLC before its rebranding in 2016.

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, focused on developing and commercializing therapeutics for severe, rare, and genetic diseases. The company's lead product, LUM-201, is an oral small molecule currently undergoing Phase 2 clinical trials for pediatric growth hormone deficiency. In addition to its primary focus, Lumos has a licensing agreement with Ellipses Pharma Limited for the development and commercialization of nanoparticle formulations aimed at oncology indications. Founded in 2011, Lumos Pharma also has a commitment to addressing Creatine Transporter Deficiency, leveraging exclusive licenses for technologies developed at the University of Cincinnati and collaborating with key opinion leaders and the National Institutes of Health. The company engages in both clinical and preclinical research, exploring treatments that may enhance immune responses against cancer, and has partnerships for manufacturing its therapeutics.

Entasis Therapeutics is a late-stage clinical biopharmaceutical company dedicated to developing innovative treatments for serious infections caused by multidrug-resistant Gram-negative bacteria, a growing global health concern. The company’s anti-infective discovery platform has led to a diverse pipeline of differentiated drug candidates, including ETX2514SUL and SUL-DUR, which target Acinetobacter baumannii, zoliflodacin for Neisseria gonorrhoeae, and ETX0282CPDP aimed at Enterobacterales. Additionally, ETX0462 is being developed to address infections caused by Pseudomonas. Through its focused efforts, Entasis Therapeutics aims to provide effective solutions for patients suffering from these challenging bacterial infections.

Forty Seven, Inc. is a clinical-stage immuno-oncology company based in Menlo Park, California, focused on developing innovative therapies to activate macrophages in the fight against cancer. The company's lead candidate, a monoclonal antibody targeting the CD47 receptor, aims to counteract the "don't eat me" signal that cancer cells use to evade the immune system. This antibody is currently undergoing evaluation in multiple clinical trials for various cancers, including solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma, and colorectal carcinoma. In addition to its flagship program, Forty Seven is advancing other antibodies, such as FSI-189, which binds to SIRPa, and FSI-174, an anti-cKIT antibody. The company has established collaborations with Genentech and Acerta Pharma to explore additional treatment combinations in non-Hodgkin's lymphoma and diffuse large B-cell lymphoma. Founded in 2014, Forty Seven operates as a subsidiary of Gilead Sciences.

ESSA Pharma Inc. is a clinical-stage pharmaceutical company based in Vancouver, Canada, specializing in the development of innovative therapies for prostate cancer. Founded in 2009, the company is currently focusing on EPI-7386, an oral drug candidate undergoing Phase I clinical trials aimed at treating patients with metastatic castration-resistant prostate cancer. ESSA's approach targets the N-terminal domain of the androgen receptor, a critical component for the growth and survival of most prostate cancer cells. By selectively blocking this domain, ESSA aims to advance the next generation of hormone therapies for patients battling advanced prostate cancer.

Gritstone bio is a biotechnology company focused on developing personalized immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surfaces of infected cells. This approach leverages the immune system's ability to recognize abnormal cell targets, which is crucial for both anti-tumor and anti-viral immunity. Gritstone bio is building a robust pipeline of immunotherapy product candidates, including GRANITE, SLATE, and CORAL, designed to address various solid tumors. Through these developments, Gritstone bio aims to contribute to the evolving landscape of cancer treatment and enhance patient outcomes.

Nuvelution Pharma, Inc. is based in Pembroke, Massachusetts, and specializes in providing capital solutions to pharmaceutical and biotechnology companies. The firm focuses on facilitating product development through risk-sharing collaborations that combine financial investment with human resources. By leveraging its extensive knowledge and relationships within the pharma and biotech sectors, Nuvelution aims to enhance the process of bringing essential medicines to patients, positioning its model as a crucial tool for these industries.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from classical complement-mediated disorders affecting the body, brain, and eye. The company's research is centered around its platform technology that targets classical complement-mediated autoimmune and neurodegenerative diseases associated with the abnormal activation of C1q, a key molecule in the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody intended for intravenous use in treating autoimmune and neurodegenerative disorders. Another candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration aimed at neurodegenerative ophthalmic conditions. The company employs a disciplined, biomarker-driven development strategy to ensure its therapies effectively engage the target at tolerable doses within the intended patient tissues, while also exploring additional indications within both orphan and larger market segments.

Flowonix Medical, Inc. is a medical device company focused on developing innovative solutions for chronic disorders through targeted drug delivery systems. The company has created an implantable drug pump designed to deliver therapeutic drugs directly into the spine, addressing the needs of patients suffering from various neurological conditions and long-term pain. Its main product, the Prometra system, includes the Prometra Pump, which ensures precise dosing, and a specialized catheter for effective drug placement within the intrathecal space. Founded in 2005 and headquartered in Mount Olive, New Jersey, with an additional office in Mansfield, Massachusetts, Flowonix aims to improve patient quality of life by providing physicians with reliable tools for managing chronic pain and neurological disorders.

Restoration Robotics is a privately held medical device company focused on advancing hair transplantation technology. It has developed the ARTAS™ System, an innovative image-guided platform that facilitates follicular unit extraction, enhancing the precision and efficiency of hair restoration procedures. By integrating advanced imaging and robotics, Restoration Robotics aims to improve outcomes for patients seeking hair transplants, positioning itself as a leader in the evolving field of hair restoration. The company is committed to transforming traditional practices through its state-of-the-art technology.

Imago BioSciences is a clinical-stage biotechnology company based in Redwood City, California, that specializes in developing innovative medicines for hematologic diseases. Founded in 2012, the company focuses on therapeutics that target genetic and epigenetic factors, specifically through the inhibition of lysine-specific demethylase 1 (LSD1), an enzyme crucial in blood cell production. Imago BioSciences aims to address significant medical challenges associated with conditions such as leukemia, myelodysplastic syndrome, and other bone marrow disorders. Its lead product candidate, Bomedemstat, is an orally available small molecule designed to treat certain myeloproliferative neoplasms, with the goal of altering disease progression and improving the quality and longevity of patients' lives.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.

SFJ Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Pleasanton, California, that focuses on the clinical development and registration of pharmaceutical products, particularly in Japan. Founded in 2008, the company aims to accelerate the availability of innovative drugs in major markets by providing funding and strategic development expertise to its pharmaceutical and biotech partners. SFJ Pharmaceuticals addresses the challenges posed by budget cuts in research and development, particularly due to pressures such as the patent cliff affecting large pharmaceutical companies and the lack of external funding for biotech firms. By assuming 100% of the clinical and regulatory risk, SFJ Pharmaceuticals enables its partners to continue advancing their key drug candidates while minimizing the impact on their financial resources. The company utilizes a platform designed for late-stage trial design, execution, and regulatory registration, facilitating the development of vital pharmaceutical products across various therapeutic areas.

Heptares Therapeutics Ltd. is a clinical-stage drug discovery company based in Welwyn Garden City, United Kingdom, founded in 2007. It specializes in developing novel small-molecule medicines that target G protein-coupled receptors (GPCRs), a significant family of druggable targets associated with various human diseases. Heptares has pioneered a proprietary technology that enables the creation of purified, stabilized, and functional GPCRs, known as StaRs (Stabilised Receptors), which addresses key challenges in the drug development process. The company offers a range of services including GPCR structure-based drug design, X-ray crystallography, surface plasmon resonance, fragment screening, and antibody discovery. Heptares has established strategic partnerships with several organizations, including Pfizer Inc., Kymab Limited, PeptiDream Inc., and Jitsubo Co., Ltd., to enhance its research and development capabilities. As of 2015, Heptares operates as a subsidiary of Sosei Group Corporation.

NanoString Technologies, Inc. is a provider of life science tools focused on translational research and molecular diagnostics, headquartered in Seattle, Washington. Established in 2003, the company utilizes a unique digital molecular barcoding technology to create a range of products that facilitate gene expression analysis, microRNA studies, and copy number variation detection. Key offerings include the nCounter Analysis System, which consists of the nCounter MAX and FLEX systems, and the nCounter SPRINT Profiler, all designed for automated sample processing and data collection. The nSolver Analysis Software aids researchers in data normalization and analysis. Additionally, NanoString provides various custom CodeSets and panels tailored for specific applications, including cancer profiling and autoimmune disease research. The company is advancing the field of spatial genomics with its GeoMx Digital Spatial Profiler system and is developing the Hyb & Seq molecular profiling system for gene sequence analysis. NanoString collaborates with several pharmaceutical companies and research institutions to enhance its product offerings and expand its impact in the scientific community.

SFJ Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Pleasanton, California, that focuses on the clinical development and registration of pharmaceutical products, particularly in Japan. Founded in 2008, the company aims to accelerate the availability of innovative drugs in major markets by providing funding and strategic development expertise to its pharmaceutical and biotech partners. SFJ Pharmaceuticals addresses the challenges posed by budget cuts in research and development, particularly due to pressures such as the patent cliff affecting large pharmaceutical companies and the lack of external funding for biotech firms. By assuming 100% of the clinical and regulatory risk, SFJ Pharmaceuticals enables its partners to continue advancing their key drug candidates while minimizing the impact on their financial resources. The company utilizes a platform designed for late-stage trial design, execution, and regulatory registration, facilitating the development of vital pharmaceutical products across various therapeutic areas.

Pearl Therapeutics is a privately held company dedicated to developing innovative therapies for prevalent respiratory diseases, including chronic obstructive pulmonary disease, rhinosinusitis, and asthma. The company specializes in creating unique dual and triple combination products, focusing on advanced inhaled therapies that are delivered through familiar metered dose inhalers. Led by a team of experienced professionals in respiratory product development, Pearl Therapeutics aims to provide patients and healthcare providers with alternatives that better address their needs. The company's goal is to enhance the safety and efficacy of existing respiratory treatments, ultimately improving clinical outcomes for individuals suffering from these conditions.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.

NanoString Technologies, Inc. is a provider of life science tools focused on translational research and molecular diagnostics, headquartered in Seattle, Washington. Established in 2003, the company utilizes a unique digital molecular barcoding technology to create a range of products that facilitate gene expression analysis, microRNA studies, and copy number variation detection. Key offerings include the nCounter Analysis System, which consists of the nCounter MAX and FLEX systems, and the nCounter SPRINT Profiler, all designed for automated sample processing and data collection. The nSolver Analysis Software aids researchers in data normalization and analysis. Additionally, NanoString provides various custom CodeSets and panels tailored for specific applications, including cancer profiling and autoimmune disease research. The company is advancing the field of spatial genomics with its GeoMx Digital Spatial Profiler system and is developing the Hyb & Seq molecular profiling system for gene sequence analysis. NanoString collaborates with several pharmaceutical companies and research institutions to enhance its product offerings and expand its impact in the scientific community.

Pearl Therapeutics is a privately held company dedicated to developing innovative therapies for prevalent respiratory diseases, including chronic obstructive pulmonary disease, rhinosinusitis, and asthma. The company specializes in creating unique dual and triple combination products, focusing on advanced inhaled therapies that are delivered through familiar metered dose inhalers. Led by a team of experienced professionals in respiratory product development, Pearl Therapeutics aims to provide patients and healthcare providers with alternatives that better address their needs. The company's goal is to enhance the safety and efficacy of existing respiratory treatments, ultimately improving clinical outcomes for individuals suffering from these conditions.

Pearl Therapeutics is a privately held company dedicated to developing innovative therapies for prevalent respiratory diseases, including chronic obstructive pulmonary disease, rhinosinusitis, and asthma. The company specializes in creating unique dual and triple combination products, focusing on advanced inhaled therapies that are delivered through familiar metered dose inhalers. Led by a team of experienced professionals in respiratory product development, Pearl Therapeutics aims to provide patients and healthcare providers with alternatives that better address their needs. The company's goal is to enhance the safety and efficacy of existing respiratory treatments, ultimately improving clinical outcomes for individuals suffering from these conditions.

SFJ Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Pleasanton, California, that focuses on the clinical development and registration of pharmaceutical products, particularly in Japan. Founded in 2008, the company aims to accelerate the availability of innovative drugs in major markets by providing funding and strategic development expertise to its pharmaceutical and biotech partners. SFJ Pharmaceuticals addresses the challenges posed by budget cuts in research and development, particularly due to pressures such as the patent cliff affecting large pharmaceutical companies and the lack of external funding for biotech firms. By assuming 100% of the clinical and regulatory risk, SFJ Pharmaceuticals enables its partners to continue advancing their key drug candidates while minimizing the impact on their financial resources. The company utilizes a platform designed for late-stage trial design, execution, and regulatory registration, facilitating the development of vital pharmaceutical products across various therapeutic areas.

SFJ Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Pleasanton, California, that focuses on the clinical development and registration of pharmaceutical products, particularly in Japan. Founded in 2008, the company aims to accelerate the availability of innovative drugs in major markets by providing funding and strategic development expertise to its pharmaceutical and biotech partners. SFJ Pharmaceuticals addresses the challenges posed by budget cuts in research and development, particularly due to pressures such as the patent cliff affecting large pharmaceutical companies and the lack of external funding for biotech firms. By assuming 100% of the clinical and regulatory risk, SFJ Pharmaceuticals enables its partners to continue advancing their key drug candidates while minimizing the impact on their financial resources. The company utilizes a platform designed for late-stage trial design, execution, and regulatory registration, facilitating the development of vital pharmaceutical products across various therapeutic areas.

Oxford Immunotec Limited is a medical diagnostics company that specializes in the development and commercialization of innovative tests for infectious and immunological diseases, leveraging its patented T-SPOT technology. This technology enables the measurement of T cell responses at a single-cell level, which aids in the diagnosis, prognosis, and monitoring of conditions regulated by the immune system. The company offers the T-SPOT.TB test, a cellular blood test designed to detect both active and latent tuberculosis infections. Additionally, it operates testing laboratories in the United States and the United Kingdom, providing access to various immunological tests for healthcare providers. Founded in 2002 and headquartered in Abingdon, United Kingdom, with operations in Marlborough, Massachusetts, Oxford Immunotec Limited serves a diverse clientele, including independent laboratories, hospital systems, and public and private institutions across the United States and internationally.

SFJ Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Pleasanton, California, that focuses on the clinical development and registration of pharmaceutical products, particularly in Japan. Founded in 2008, the company aims to accelerate the availability of innovative drugs in major markets by providing funding and strategic development expertise to its pharmaceutical and biotech partners. SFJ Pharmaceuticals addresses the challenges posed by budget cuts in research and development, particularly due to pressures such as the patent cliff affecting large pharmaceutical companies and the lack of external funding for biotech firms. By assuming 100% of the clinical and regulatory risk, SFJ Pharmaceuticals enables its partners to continue advancing their key drug candidates while minimizing the impact on their financial resources. The company utilizes a platform designed for late-stage trial design, execution, and regulatory registration, facilitating the development of vital pharmaceutical products across various therapeutic areas.

Sientra is a medical device company based in Santa Barbara, California, specializing in breast implant treatments for both augmentation and reconstruction. Founded by Hani Zeini, the company develops innovative implantable devices that cater to the needs of plastic surgeons. Sientra's product offerings include silicone gel breast implants, breast tissue expanders, and silicone scar treatment solutions, focusing on providing elegant and intuitive options for cosmetic and reconstructive surgery. The company's commitment to quality and innovation positions it as a significant player in the surgical aesthetics market.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company specializes in developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By focusing on these mechanisms, Cleave Therapeutics aims to create enzyme inhibitors that can effectively treat cancer and neurodegenerative diseases. Its research efforts are directed toward discovering innovative therapies that may improve patient outcomes in oncology.

NanoString Technologies, Inc. is a provider of life science tools focused on translational research and molecular diagnostics, headquartered in Seattle, Washington. Established in 2003, the company utilizes a unique digital molecular barcoding technology to create a range of products that facilitate gene expression analysis, microRNA studies, and copy number variation detection. Key offerings include the nCounter Analysis System, which consists of the nCounter MAX and FLEX systems, and the nCounter SPRINT Profiler, all designed for automated sample processing and data collection. The nSolver Analysis Software aids researchers in data normalization and analysis. Additionally, NanoString provides various custom CodeSets and panels tailored for specific applications, including cancer profiling and autoimmune disease research. The company is advancing the field of spatial genomics with its GeoMx Digital Spatial Profiler system and is developing the Hyb & Seq molecular profiling system for gene sequence analysis. NanoString collaborates with several pharmaceutical companies and research institutions to enhance its product offerings and expand its impact in the scientific community.

Restoration Robotics is a privately held medical device company focused on advancing hair transplantation technology. It has developed the ARTAS™ System, an innovative image-guided platform that facilitates follicular unit extraction, enhancing the precision and efficiency of hair restoration procedures. By integrating advanced imaging and robotics, Restoration Robotics aims to improve outcomes for patients seeking hair transplants, positioning itself as a leader in the evolving field of hair restoration. The company is committed to transforming traditional practices through its state-of-the-art technology.

SARcode Bioscience is a private biopharmaceutical company based in San Francisco that focuses on developing a novel class of small molecule antagonists targeting lymphocyte function-associated antigen-1 (LFA-1). These antagonists are being developed as topical agents aimed at addressing significant unmet medical needs in the fields of ophthalmology, dermatology, and other inflammatory diseases. By targeting LFA-1, SARcode aims to create innovative treatments that can improve patient outcomes in these areas.

Aerie Pharmaceuticals is a biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases. Founded in 2005, the company has its headquarters in Bridgewater, New Jersey, and research facilities in Research Triangle Park, North Carolina. Aerie's portfolio includes Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; Rocklatan, a fixed-dose combination of Rhopressa and latanoprost for similar indications; AVX-012, a clinical-stage product candidate for dry eye; and AR-1105 and AR-13503 sustained-release implants for retinal diseases. The company collaborates with DSM on research, development, and licensing agreements.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.

TyRx specializes in the design, development, and commercialization of resorbable polymeric biomaterials, focusing on drug-device combination products. The company offers PIVIT CRM, a mesh-based pouch designed to protect against microbial colonization of surgical implants such as generators and defibrillators during and immediately after surgery. Additionally, TyRx provides AIGISRx Flat, an antibacterial solution aimed at preventing infections linked to implanted pacemakers and defibrillators. Founded in 1997 and headquartered in Monmouth Junction, New Jersey, TyRx is committed to advancing medical technology through innovative products that enhance patient safety.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

Taligen Therapeutics is dedicated to discovering and developing innovative protein therapeutics aimed at modulating the alternative pathway of the complement system. This approach targets a range of inflammatory conditions and diseases. The company's primary therapeutic candidates include monoclonal antibodies and recombinant fusion proteins designed to address key factors in the alternative pathway, which has been identified as a significant mechanism in the inflammatory response. By focusing on the regulation of the complement system, Taligen Therapeutics seeks to create effective treatments for various inflammatory and immune diseases.

Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company based in Blue Bell, Pennsylvania, focused on discovering and developing small molecule drug therapies for immune system disorders. The company's lead candidate, ACH-4471, is a factor D inhibitor currently undergoing Phase II clinical trials for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy. Additionally, Achillion is developing two other factor D inhibitors, ACH-5228 and ACH-5548, both in Phase I clinical trials for PNH and other complement-mediated diseases. The company also has licensing agreements with Ora, Inc. for the development of ACH-702, and with GCA Therapeutics, Ltd. for elvucitabine, a treatment for hepatitis B and HIV. Founded in 1998, Achillion aims to advance its portfolio of therapies targeting the complement system, which plays a crucial role in various immune-related conditions.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases, particularly within the central nervous system. The company is headquartered in Emeryville, California, and was established in 2006. Its lead product candidate, Fintepla, is a low-dose fenfluramine currently undergoing Phase III clinical trials for the treatment of seizures related to Dravet syndrome and Lennox-Gastaut syndrome. Additionally, it is being investigated in Phase II trials for other rare epileptic conditions. Zogenix is also developing MT1621, a therapy aimed at treating inherited mitochondrial DNA depletion disorders. Furthermore, the company collaborates with Tevard Biosciences to explore gene therapies for Dravet syndrome and similar genetic epilepsies. By focusing on therapies that address significant unmet medical needs, Zogenix aims to enhance the quality of life for patients and their families.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

Oxford Immunotec Limited is a medical diagnostics company that specializes in the development and commercialization of innovative tests for infectious and immunological diseases, leveraging its patented T-SPOT technology. This technology enables the measurement of T cell responses at a single-cell level, which aids in the diagnosis, prognosis, and monitoring of conditions regulated by the immune system. The company offers the T-SPOT.TB test, a cellular blood test designed to detect both active and latent tuberculosis infections. Additionally, it operates testing laboratories in the United States and the United Kingdom, providing access to various immunological tests for healthcare providers. Founded in 2002 and headquartered in Abingdon, United Kingdom, with operations in Marlborough, Massachusetts, Oxford Immunotec Limited serves a diverse clientele, including independent laboratories, hospital systems, and public and private institutions across the United States and internationally.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.

Lycera is a preclinical-stage biopharmaceutical company dedicated to the development of small molecule immunomodulators aimed at treating autoimmune diseases such as rheumatoid arthritis, lupus erythematosus, and inflammatory bowel disease. The company specializes in creating first-in-class drugs that utilize proprietary small molecules to modulate key targets involved in cellular bioenergetics and the Th17 pathway. Lycera's innovative approach seeks to provide effective oral therapies that minimize the adverse effects commonly associated with existing antiproliferative and immunosuppressive treatments. By focusing on the development of these novel agents, Lycera aims to improve patient outcomes in the management of immune disorders.

NanoString Technologies, Inc. is a provider of life science tools focused on translational research and molecular diagnostics, headquartered in Seattle, Washington. Established in 2003, the company utilizes a unique digital molecular barcoding technology to create a range of products that facilitate gene expression analysis, microRNA studies, and copy number variation detection. Key offerings include the nCounter Analysis System, which consists of the nCounter MAX and FLEX systems, and the nCounter SPRINT Profiler, all designed for automated sample processing and data collection. The nSolver Analysis Software aids researchers in data normalization and analysis. Additionally, NanoString provides various custom CodeSets and panels tailored for specific applications, including cancer profiling and autoimmune disease research. The company is advancing the field of spatial genomics with its GeoMx Digital Spatial Profiler system and is developing the Hyb & Seq molecular profiling system for gene sequence analysis. NanoString collaborates with several pharmaceutical companies and research institutions to enhance its product offerings and expand its impact in the scientific community.

Pearl Therapeutics is a privately held company dedicated to developing innovative therapies for prevalent respiratory diseases, including chronic obstructive pulmonary disease, rhinosinusitis, and asthma. The company specializes in creating unique dual and triple combination products, focusing on advanced inhaled therapies that are delivered through familiar metered dose inhalers. Led by a team of experienced professionals in respiratory product development, Pearl Therapeutics aims to provide patients and healthcare providers with alternatives that better address their needs. The company's goal is to enhance the safety and efficacy of existing respiratory treatments, ultimately improving clinical outcomes for individuals suffering from these conditions.

Neomend is a biomedical device company focused on developing and commercializing innovative surgical wound healing products. The company utilizes its proprietary platform technology, Pro/PEG, which is a bioadhesive polymer hydrogel. Neomend specializes in a combination wound sealant and adhesion barrier product designed for use during minimally invasive or laparoscopic surgical procedures, aiming to enhance patient outcomes and improve recovery times.

IVERIC bio is a biopharmaceutical company dedicated to discovering and developing innovative treatment options for retinal diseases that have significant unmet medical needs. The company is actively working on therapeutic product candidates aimed at age-related retinal diseases, as well as gene therapy product candidates designed for orphan inherited retinal diseases. Through its focused research and development efforts, IVERIC bio seeks to address critical gaps in the treatment landscape for patients suffering from these conditions.

Virdante Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the development and commercialization of drugs for autoimmune and inflammatory diseases. Founded in 2007 and previously known as Centaurus Pharmaceuticals, the company specializes in creating antibody and Fc-fusion therapies aimed at addressing various autoimmune conditions. Through its innovative research and development efforts, Virdante Pharmaceuticals seeks to improve treatment options for patients suffering from these disorders.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases, particularly within the central nervous system. The company is headquartered in Emeryville, California, and was established in 2006. Its lead product candidate, Fintepla, is a low-dose fenfluramine currently undergoing Phase III clinical trials for the treatment of seizures related to Dravet syndrome and Lennox-Gastaut syndrome. Additionally, it is being investigated in Phase II trials for other rare epileptic conditions. Zogenix is also developing MT1621, a therapy aimed at treating inherited mitochondrial DNA depletion disorders. Furthermore, the company collaborates with Tevard Biosciences to explore gene therapies for Dravet syndrome and similar genetic epilepsies. By focusing on therapies that address significant unmet medical needs, Zogenix aims to enhance the quality of life for patients and their families.

NanoString Technologies, Inc. is a provider of life science tools focused on translational research and molecular diagnostics, headquartered in Seattle, Washington. Established in 2003, the company utilizes a unique digital molecular barcoding technology to create a range of products that facilitate gene expression analysis, microRNA studies, and copy number variation detection. Key offerings include the nCounter Analysis System, which consists of the nCounter MAX and FLEX systems, and the nCounter SPRINT Profiler, all designed for automated sample processing and data collection. The nSolver Analysis Software aids researchers in data normalization and analysis. Additionally, NanoString provides various custom CodeSets and panels tailored for specific applications, including cancer profiling and autoimmune disease research. The company is advancing the field of spatial genomics with its GeoMx Digital Spatial Profiler system and is developing the Hyb & Seq molecular profiling system for gene sequence analysis. NanoString collaborates with several pharmaceutical companies and research institutions to enhance its product offerings and expand its impact in the scientific community.

Lycera is a preclinical-stage biopharmaceutical company dedicated to the development of small molecule immunomodulators aimed at treating autoimmune diseases such as rheumatoid arthritis, lupus erythematosus, and inflammatory bowel disease. The company specializes in creating first-in-class drugs that utilize proprietary small molecules to modulate key targets involved in cellular bioenergetics and the Th17 pathway. Lycera's innovative approach seeks to provide effective oral therapies that minimize the adverse effects commonly associated with existing antiproliferative and immunosuppressive treatments. By focusing on the development of these novel agents, Lycera aims to improve patient outcomes in the management of immune disorders.

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

SFJ Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Pleasanton, California, that focuses on the clinical development and registration of pharmaceutical products, particularly in Japan. Founded in 2008, the company aims to accelerate the availability of innovative drugs in major markets by providing funding and strategic development expertise to its pharmaceutical and biotech partners. SFJ Pharmaceuticals addresses the challenges posed by budget cuts in research and development, particularly due to pressures such as the patent cliff affecting large pharmaceutical companies and the lack of external funding for biotech firms. By assuming 100% of the clinical and regulatory risk, SFJ Pharmaceuticals enables its partners to continue advancing their key drug candidates while minimizing the impact on their financial resources. The company utilizes a platform designed for late-stage trial design, execution, and regulatory registration, facilitating the development of vital pharmaceutical products across various therapeutic areas.

Heptares Therapeutics Ltd. is a clinical-stage drug discovery company based in Welwyn Garden City, United Kingdom, founded in 2007. It specializes in developing novel small-molecule medicines that target G protein-coupled receptors (GPCRs), a significant family of druggable targets associated with various human diseases. Heptares has pioneered a proprietary technology that enables the creation of purified, stabilized, and functional GPCRs, known as StaRs (Stabilised Receptors), which addresses key challenges in the drug development process. The company offers a range of services including GPCR structure-based drug design, X-ray crystallography, surface plasmon resonance, fragment screening, and antibody discovery. Heptares has established strategic partnerships with several organizations, including Pfizer Inc., Kymab Limited, PeptiDream Inc., and Jitsubo Co., Ltd., to enhance its research and development capabilities. As of 2015, Heptares operates as a subsidiary of Sosei Group Corporation.

Biolex is a clinical-stage biopharmaceutical company that uses their patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates. Their main product aims at treating those afflicted with Hepatitis C.

Link Medicine, founded in 2005 by Peter Lansbury, Ed Rudman, and Adam Rosenberg, is a biotechnology company focused on developing innovative treatments for neurodegenerative diseases. The founders have personal connections to these conditions, with Lansbury being a prominent neuroscience researcher from Harvard University, and Rudman and Rosenberg having family experiences with Parkinson's disease and Alzheimer's. The company is dedicated to addressing various neurodegenerative disorders, including Alzheimer's, Parkinson's, Huntington's disease, and Amyotrophic Lateral Sclerosis (ALS). Link Medicine's research targets a critical aspect of these diseases: the accumulation of misfolded, aggregated proteins in nerve cells, which contribute to neurotoxicity and disease progression.

ESBATech, founded in 1998 as a spin-off from the University of Zurich, specializes in the development of fully human antibody fragments for therapeutic purposes. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant diseases. ESBATech aims to deliver high concentrations of these therapeutic antibody fragments to specific sites while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions. In addition to its innovative antibody development, the company offers drug development services and manages various development programs, positioning itself as a leader in the field of targeted therapies.

MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, specializing in the discovery and development of antibody-based therapeutics for cancer treatment. Founded in 2000, the company focuses on immuno-oncology and has a diverse pipeline of product candidates. Key developments include Margetuximab, a monoclonal antibody in Phase III clinical trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other investigational products include MGA012, MGD013, MGD019, and Enoblituzumab, which target various immune checkpoints and tumor-associated antigens. MacroGenics is also advancing combination therapies and antibody-drug conjugates, such as MGC018, which targets solid tumors expressing B7-H3. The company has formed strategic collaborations with notable partners, enhancing its research and development efforts in the biopharmaceutical landscape.

Pearl Therapeutics is a privately held company dedicated to developing innovative therapies for prevalent respiratory diseases, including chronic obstructive pulmonary disease, rhinosinusitis, and asthma. The company specializes in creating unique dual and triple combination products, focusing on advanced inhaled therapies that are delivered through familiar metered dose inhalers. Led by a team of experienced professionals in respiratory product development, Pearl Therapeutics aims to provide patients and healthcare providers with alternatives that better address their needs. The company's goal is to enhance the safety and efficacy of existing respiratory treatments, ultimately improving clinical outcomes for individuals suffering from these conditions.

CoMentis, Inc. is a biotechnology company dedicated to the research, discovery, and development of small-molecule drugs aimed at treating neurovascular diseases, particularly Alzheimer's disease and schizophrenia. The company is focused on creating nicotinic acetylcholine receptor modulators to address cognitive disorders. Founded in 2004 as Athenagen, Inc., it underwent a name change to CoMentis in February 2007 after merging with Zapaq, Inc., which strengthened its position in the neurovascular disease sector. CoMentis is headquartered in South San Francisco, California.

Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases, particularly within the central nervous system. The company is headquartered in Emeryville, California, and was established in 2006. Its lead product candidate, Fintepla, is a low-dose fenfluramine currently undergoing Phase III clinical trials for the treatment of seizures related to Dravet syndrome and Lennox-Gastaut syndrome. Additionally, it is being investigated in Phase II trials for other rare epileptic conditions. Zogenix is also developing MT1621, a therapy aimed at treating inherited mitochondrial DNA depletion disorders. Furthermore, the company collaborates with Tevard Biosciences to explore gene therapies for Dravet syndrome and similar genetic epilepsies. By focusing on therapies that address significant unmet medical needs, Zogenix aims to enhance the quality of life for patients and their families.

Taligen Therapeutics is dedicated to discovering and developing innovative protein therapeutics aimed at modulating the alternative pathway of the complement system. This approach targets a range of inflammatory conditions and diseases. The company's primary therapeutic candidates include monoclonal antibodies and recombinant fusion proteins designed to address key factors in the alternative pathway, which has been identified as a significant mechanism in the inflammatory response. By focusing on the regulation of the complement system, Taligen Therapeutics seeks to create effective treatments for various inflammatory and immune diseases.

Pelikan Technologies is dedicated to the development of innovative hand-held diagnostic and monitoring devices capable of significantly improving the screening and management of a variety of medical conditions.

Oxford Immunotec Limited is a medical diagnostics company that specializes in the development and commercialization of innovative tests for infectious and immunological diseases, leveraging its patented T-SPOT technology. This technology enables the measurement of T cell responses at a single-cell level, which aids in the diagnosis, prognosis, and monitoring of conditions regulated by the immune system. The company offers the T-SPOT.TB test, a cellular blood test designed to detect both active and latent tuberculosis infections. Additionally, it operates testing laboratories in the United States and the United Kingdom, providing access to various immunological tests for healthcare providers. Founded in 2002 and headquartered in Abingdon, United Kingdom, with operations in Marlborough, Massachusetts, Oxford Immunotec Limited serves a diverse clientele, including independent laboratories, hospital systems, and public and private institutions across the United States and internationally.

Pearl Therapeutics is a privately held company dedicated to developing innovative therapies for prevalent respiratory diseases, including chronic obstructive pulmonary disease, rhinosinusitis, and asthma. The company specializes in creating unique dual and triple combination products, focusing on advanced inhaled therapies that are delivered through familiar metered dose inhalers. Led by a team of experienced professionals in respiratory product development, Pearl Therapeutics aims to provide patients and healthcare providers with alternatives that better address their needs. The company's goal is to enhance the safety and efficacy of existing respiratory treatments, ultimately improving clinical outcomes for individuals suffering from these conditions.

Globus Medical, Inc. is a medical device company specializing in the development and commercialization of implants for patients with musculoskeletal disorders. Founded in 2003 and headquartered in Audubon, Pennsylvania, the company offers a diverse range of products for spinal treatment, addressing conditions such as degenerative diseases, deformities, tumors, and trauma affecting the spine. Its spine product portfolio includes surgical options and implants, alongside orthopedic trauma solutions like fracture plates and compression screws. Globus Medical also provides regenerative biologic products, motion preservation technologies, and interventional pain management solutions. Additionally, the company develops imaging, navigation, and robotic-assisted surgery technologies, as well as hip and knee joint solutions. Globus Medical aims to leverage engineering and technological advancements to improve surgical outcomes and enhance the quality of life for patients suffering from spinal disorders. The majority of its revenue is derived from its musculoskeletal solutions, with a significant portion generated within the United States.

Sientra is a medical device company based in Santa Barbara, California, specializing in breast implant treatments for both augmentation and reconstruction. Founded by Hani Zeini, the company develops innovative implantable devices that cater to the needs of plastic surgeons. Sientra's product offerings include silicone gel breast implants, breast tissue expanders, and silicone scar treatment solutions, focusing on providing elegant and intuitive options for cosmetic and reconstructive surgery. The company's commitment to quality and innovation positions it as a significant player in the surgical aesthetics market.

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

Proacta Inc. is a private, clinical-stage, biopharmaceutical company headquartered in San Diego, California. They are focused on addressing unmet needs in the field of cancer with the development of hypoxia-activated prodrugs that target cancer cells. Proacta was founded on intellectual property generated in New Zealand at the University of Auckland and in the United States at Stanford University. Proacta's patent family covers a series of hypoxia-activated prodrugs designed to treat cancer. Expansion of this portfolio is supported by ongoing research at The University of Auckland. PR610 is the lead compound from their pipeline of pro-drugs based on hypoxia-activated tyrosine-kinase inhibitors. These pro-drugs selectively release active tyrosine-kinase inhibitors within the low-oxygen (hypoxic) environment found in many solid tumors. By shifting the release of active drug away from normal tissues and into cancer tissues, these drugs are predicted to be more effective and less toxic than currently available therapies. To date, Proacta has raised $43 million in two private financings. Investors include Alta Partners, Clarus Ventures, Delphi Ventures, Endeavour Capital (New Zealand), GBS Venture Partners (Australia), Genentech, No 8 Ventures (New Zealand) and Roche.

SARcode Bioscience is a private biopharmaceutical company based in San Francisco that focuses on developing a novel class of small molecule antagonists targeting lymphocyte function-associated antigen-1 (LFA-1). These antagonists are being developed as topical agents aimed at addressing significant unmet medical needs in the fields of ophthalmology, dermatology, and other inflammatory diseases. By targeting LFA-1, SARcode aims to create innovative treatments that can improve patient outcomes in these areas.

VBI Vaccines Inc. is a biopharmaceutical company focused on developing and commercializing vaccines for infectious diseases and immuno-oncology, operating in Israel, the United States, and internationally. The company’s flagship product, Sci-B-Vac, is a commercial-stage hepatitis B vaccine that effectively mimics all three viral surface antigens, providing rapid protection and high antibody levels with lower dosing requirements compared to traditional vaccines. VBI's innovative enveloped virus-like particle (eVLP) platform technology facilitates the creation of vaccines that closely resemble target viruses, enhancing immune responses. The company is advancing several clinical programs, including VBI-1901, an immunotherapeutic candidate for glioblastoma, and VBI-1501, a prophylactic vaccine for cytomegalovirus. VBI collaborates with various organizations, including Brii Biosciences and GlaxoSmithKline, and partners with the National Research Council of Canada to develop a pan-coronavirus vaccine. Headquartered in Cambridge, Massachusetts, VBI Vaccines Inc. aims to address unmet medical needs through its innovative vaccine solutions.

SARcode Bioscience is a private biopharmaceutical company based in San Francisco that focuses on developing a novel class of small molecule antagonists targeting lymphocyte function-associated antigen-1 (LFA-1). These antagonists are being developed as topical agents aimed at addressing significant unmet medical needs in the fields of ophthalmology, dermatology, and other inflammatory diseases. By targeting LFA-1, SARcode aims to create innovative treatments that can improve patient outcomes in these areas.

CoMentis, Inc. is a biotechnology company dedicated to the research, discovery, and development of small-molecule drugs aimed at treating neurovascular diseases, particularly Alzheimer's disease and schizophrenia. The company is focused on creating nicotinic acetylcholine receptor modulators to address cognitive disorders. Founded in 2004 as Athenagen, Inc., it underwent a name change to CoMentis in February 2007 after merging with Zapaq, Inc., which strengthened its position in the neurovascular disease sector. CoMentis is headquartered in South San Francisco, California.

Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases, particularly within the central nervous system. The company is headquartered in Emeryville, California, and was established in 2006. Its lead product candidate, Fintepla, is a low-dose fenfluramine currently undergoing Phase III clinical trials for the treatment of seizures related to Dravet syndrome and Lennox-Gastaut syndrome. Additionally, it is being investigated in Phase II trials for other rare epileptic conditions. Zogenix is also developing MT1621, a therapy aimed at treating inherited mitochondrial DNA depletion disorders. Furthermore, the company collaborates with Tevard Biosciences to explore gene therapies for Dravet syndrome and similar genetic epilepsies. By focusing on therapies that address significant unmet medical needs, Zogenix aims to enhance the quality of life for patients and their families.

ESBATech, founded in 1998 as a spin-off from the University of Zurich, specializes in the development of fully human antibody fragments for therapeutic purposes. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant diseases. ESBATech aims to deliver high concentrations of these therapeutic antibody fragments to specific sites while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions. In addition to its innovative antibody development, the company offers drug development services and manages various development programs, positioning itself as a leader in the field of targeted therapies.